行情

ARQL

ARQL

ArQule
NASDAQ

实时行情|Nasdaq Last Sale

20.00
+0.03
+0.15%
已退市 09:30 01/24 EST
开盘
20.00
昨收
19.97
最高
20.00
最低
19.98
成交量
617.26万
成交额
--
52周最高
20.45
52周最低
3.150
市值
24.15亿
市盈率(TTM)
-58.1564
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ARQL 新闻

  • WeWork与软银投资的Gympass签署共享办公空间协议
  • 新浪美股.2小时前
  • NBA神话人物陨落,球星科比坠机身亡
  • 第一财经.3小时前
  • 投资人科比:创办基金公司 投资阿里
  • 新浪科技综合.4小时前
  • 突发!NBA球星科比遭遇直升机意外丧生
  • 新浪财经综合.4小时前

更多

所属板块

生物技术和医学研究
-2.64%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

ARQL 简况

ArQule, Inc. is a biopharmaceutical company that is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focus on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of approximately four drug candidates, all of which are in targeted patient populations. The Company's product candidates include ARQ 531, Miransertib (ARQ 092), ARQ 751, Miransertib (ARQ 092) and ARQ 751. ARQ 531 is a potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK). ARQ 092 is a potent and selective inhibitor of protein kinase B (AKT), a serine/threonine kinase. ARQ 751 is a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase (PI3K). ARQ 087 is a multi-kinase inhibitor designed to preferentially inhibit the fibroblast.
展开

Webull提供ArQule, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。